Lenvima 10 mg Alternative – Lenvaxen (Lenvatinib) 10 mg Capsule | Everest Pharmaceuticals
Lenvaxen 10 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 10 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Lenvaxen 10 mg Capsule by Everest Pharmaceuticals Ltd., Bangladesh contains Lenvatinib. It is listed here as a same-ingredient branded option for people researching Lenvima, a reference brand associated with Eisai. Lenvaxen and Lenvima must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 10 mg strength.
Lenvaxen vs. Lenvima – Originator / Reference Brand Comparison
Lenvima is a widely recognized reference brand for Lenvatinib associated with Eisai. Lenvaxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Lenvaxen is manufactured by Eisai, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Lenvatinib
Strength: 10 mg
Dosage form: Capsule
Pharmacological class: multikinase inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Lenvatinib is used in selected thyroid, renal, liver and endometrial cancer regimens. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Lenvatinib Works
Lenvatinib is a multikinase inhibitor. In general, it blocks VEGFR, FGFR and other kinase pathways. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 10 mg per capsule; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Lenvatinib include: high blood pressure, proteinuria, bleeding and diarrhea. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Lenvatinib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include high blood pressure, proteinuria, bleeding and diarrhea. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Lenvatinib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Lenvatinib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Lenvaxen Listed as an Alternative to Lenvima?
This listing helps customers identify an Everest Pharmaceuticals product containing Lenvatinib while researching Lenvima. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Lenvaxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Lenvima
Reference company: Eisai
Generic ingredient: Lenvatinib
Strength: 10 mg
Dosage form: Capsule
Therapeutic class: multikinase inhibitor
Frequently Asked Questions
What is Lenvaxen 10 mg?
It is an Everest Pharmaceuticals capsule containing Lenvatinib 10 mg.
Is Lenvaxen the same as Lenvima?
They are presented as brands associated with Lenvatinib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Lenvatinib used for?
Lenvatinib is used in selected thyroid, renal, liver and endometrial cancer regimens, subject to the applicable label and clinical assessment.
How does Lenvatinib work?
It blocks VEGFR, FGFR and other kinase pathways.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Lenvatinib |
|---|---|
| Strength | 10 mg |
| Dosage Form | Capsule |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 14 or 30 capsules; verify exact pack for each strength |
Related products
Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Balversa 4 mg Alternative – Erdarixen (Erdafitinib) 4 mg Tablet | Everest Pharmaceuticals
Erdarixen 4 mg (Erdafitinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Balversa (Janssen). It belongs to the FGFR inhibitor class and is used in selected FGFR-altered urothelial cancer.
Active ingredient: Erdafitinib
Strength: 4 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Erleada 60 mg Alternative – Prostaxen (Apalutamide) 60 mg Tablet | Everest Pharmaceuticals
Prostaxen 60 mg (Apalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Erleada (Janssen). It belongs to the androgen receptor inhibitor class and is used in selected castration-resistant or castration-sensitive prostate cancer settings.
Active ingredient: Apalutamide
Strength: 60 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Megace 160 mg Alternative – Mezoxia (Megestrol acetate) 160 mg Tablet | Everest Pharmaceuticals
Mezoxia 160 mg (Megestrol acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Megace (Bristol Myers Squibb). It belongs to the progestin class and is used in certain hormone-responsive cancer settings depending on formulation and jurisdiction.
Active ingredient: Megestrol acetate
Strength: 160 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals
Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.
Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.